US 2020/0268679 Al  22  Aug. 27, 2020  98.  The method according to claim  97,  further comprising  dissolving a polymer into the organic stream.  99.  The method according to any one of claims  97  and  98,  wherein the organic stream is water-miscible.  100.  The method according to claim  91,  wherein the  nanoparticles are formed by  dissolving the API in a polar solvent to form a polar  solution stream,  dissolving the IP in an organic solvent to form an organic  solution stream, and  continuously mixing the polar solution stream against the  organic solution stream to form a mixed solution from  which the nanoparticles that encapsulate the API  assemble and precipitate,  wherein the organic solvent is less polar than the polar  solvent.  101.  The method according to claim  100,  further com› prising dissolving a polymer into the organic solvent.  102.  The method according to any one of claims  100  and  101,  wherein the organic solvent is water-miscible.  103.  The method according to claim  91,  wherein the  nanoparticles are formed by an emulsion/stripping process.  104.  The method according to any one of claims  91  through  103  wherein the API is an antibacterial.  105.  The method according to any one of claims  91  through  104,  wherein the API is a biologic.  106.  The method according to any one of claims  91  through  104,  wherein the API is selected from the group  consisting of: an antimicrobial small molecule, a peptide, a  cationic peptide, an anionic peptide, a protein, a cationic  protein, an anionic protein, and an aminoglycoside.  107.  The method according to any one of claims  91  through  106,  wherein the API has an aqueous solubility of  greater than 10 mg/ml.  108.  The method according to any one of claims  91  through  107,  wherein the API has a log P value less than -2  in an aqueous solution at pH of 7.  109.  The method according to any one of claims  91  through  108,  wherein the API has 1, 2, 3, 4, 5, 6, or more  ionic groups.  110.  The method according to any one of claims  91  through  105  and  107  through  109,  wherein the API is not an  oligonucleotide.  111.  The method according to any one of claims  91  through  103,  wherein the API is selected from the group  consisting of gentamycin, polymyxin B, mastoparan 7, sub5,  LL37, colistin, ecumicin, OZ439, ovalbumin, and lysozyme.  112.  The method according to any one of claims  91  through  103,  wherein the API is selected from the group  consisting of polymyxin B, colistin, mastoparan 7, sub5,  ovalbumin, and gentamycin.  113.  The method according to any one of claims  91  through  112,  wherein the counterion has a log P value of 2  or greater at a pH of 7.  114.  The method according to any one of claims  91  through  112,  wherein the counterion has a log P value of  greater than 5 and the release profile of the API displays a  plateau in the release rate or fraction released with time.  115.  The method according to any one of claims  91  through  114,  wherein the counterion has 1, 2, or more ionic  sites.  116.  The method according to any one of claims  91  through  115,  wherein the counterion is an anionic counterion  that has a pKa value of from -2 to 5.  117.  The method according to any one of claims  91  through  115,  wherein the counterion has a pKb value of  greater than 3.  118.  The method according to any one of claims  91  through  115,  wherein the counterion is a quatemized cat› ionic species that is permanently cationic.  119.  The method according to any one of claims  91  through  115,  wherein the counterion has an ionic site  selected from the group consisting of a carboxylic acid,  sulfate, sulfonate, or amine.  120.  The method according to any one of claims  91  through  112,  wherein the IP reagent is selected from the  group consisting of sodium hexanoate, sodium decanoate,  sodium myristate (MA), sodium oleate (OA), pamoic acid  disodium salt (PA), benzenesulfonic acid monohydrate,  sodium 2-naphthalenesulfonate, (lR)-(-)-10-camphorsulfo› nic acid, sodium 1,2-ethanesulfonate, sodium 1-heptanesul› fonate, sodium 1-octanesulfonate monohydrate, sodium  1-decanesulfonate, sodium dodecyl sulfate (SDS), sodium  dodecylbenzene sulfonate (DBS), and sodium deoxycholate.  121.  The method according to any one of claims  91  through  112,  wherein the IP reagent is sodium decyl sulfate  (DS).  122.  The method according to any one of claims  91  through  112,  wherein the counterion is selected from the  group consisting of dodecyl hydrogen sulfate, decyl hydro› gen sulfate, dodecylbenzene sulfonic acid, myristic acid,  oleic acid, and pamoic acid.  123.  The method according to any one of claims  91  through  112,  wherein the counterion is selected from the  group consisting of oleic acid and palmitic acid.  124.  The method according to any one of claims  93  through  96, 98  through  99, 101  through  102,  and  104  through  123,  wherein the polymer is self-assembling.  125.  The method according to any one of claims  93  through  96, 98  through  99, 101  through  102,  and  104  through  123,  wherein the polymer is selected from the group  consisting of hydroxypropyl methylcellulose acetate succi› nate (HPMCAS), polystyrene-block-polyethylene glycol  (PS-b-PEG), and polycaprolactone-block-polyethylene gly› col (PCL-b-PEG).  126.  The method according to any one of claims  93  through  96, 98  through  99, 101  through  102,  and  104  through  123,  wherein the polymer is selected from the group  consisting of 1.6 kDa polystyrene-block-5 kDa polyethylene  glycol and 5 kDa polycaprolactone-block-5 kDa polyethyl› ene glycol.  127.  The method according to any one of claims  91  through  126,  further comprising a polyethylene glycol coat› ing on the nanoparticles.  128.  The method according to any one of claims  91  through  127,  wherein the nanoparticles have a Z-average  particle size of from 10 nm to 1000 nm.  129.  The method according to any one of claims  91  through  127,  wherein the nanoparticles have a Z-average  particle size of from 25 nm to 1200 nm.  130.  The method according to any one of claims  91  through  127,  wherein the nanoparticles have a Z-average  particle size of from 50 nm to 500 nm.  131.  The method according to any one of claims  91  through  127,  wherein the nanoparticles have a Z-average  particle size of from 75 nm to 400 nm. 